The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.
|Articles|February 10, 2022
Daily Medication Pearl: Diroximel Fumarate (Vumerity)
Author(s)Saro Arakelians, PharmD
Diroximel fumarate (Vumerity) is indicated for the treatment of relapsing forms of multiple sclerosis.
Advertisement
Medication Pearl of the Day: Diroximel fumarate (Vumerity)
Indication: Diroximel fumarate (Vumerity)is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Insight:
- Dosing: Starting dose 231 mg twice a day, orally, for 7 days. Maintenance dose after 7 days 462 mg administered as two 231 mg capsules twice a day, orally.
- Dosage forms: Delayed-release capsules 231 mg.
- Adverse events: Most common adverse reactions for dimethyl fumarate were flushing, abdominal pain, diarrhea, and nausea.
- Mechanism of action: MMF, the active metabolite of diroximel fumarate, has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro.
- Manufacturer: Biogen
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: Symptoms, Antibiotics, and Current US Risk
2
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
3
Intensive BP Control Cuts CV Risk Regardless of CKD Status
4
Inside the New Consensus Recommendations for Acute Stroke Care
5